These data suggest that miR-146a-5p plays an indirect role in anti-inflammatory and antifibrotic effects through the negative regulation of the downstream target genes traf6 and irak1. Overall, miR-146a-5p was enriched in UC-sEvs produced under GMP guidance and expressed stably in different batches; therefore, it is suitable as a potent molecule for IPF treatment. The gene discussed is IRAK1; the disease is idiopathic pulmonary fibrosis.